

1/9




Fig.1. Location of topographical epitopes on CD30 molecule

BEST AVAILABLE COPY

10/516766


2/9

Fig 2a. Amino acid sequences of the variable regions of anti-CD30 MAbs

SEQ ID	FR1	FR2	CDR1	CDR2	FR3	CDR3	FR4				
NO:	1	2	3	4	5	6	7	8	9	10	11
123456789012345678901234567890	123456789012345678901234567890	12345AB 67890123456789	12345AB 67890123456789	012ABC3456789012345	67890123456789012345678901234	567890ABCDEFHJKL12	34567890123				
T6	2	QVQLKESGPGGLVTPSQSLSTICTVSGFSL	KYSIH	WVRQPPGQGLEWIG	MIW---	GVENTDYNALKS	RLSISKDNKSKQVFLKVNLSQSDDTAMYYCAR	KDLGLYGM-----	NY	WGQGISVTVSA	
T7	3	QVQLQSGAELVRPGSSVKLSCKASGYTFS	SYWMN	WMKQPPGQGLEWIG	QIYP--	GDDDTNYNGKFKG	KATLTADKSSSTAYMQLSSLTSEDSAVYFCAR	RETRGAMF-----	TY	WGQGTLLVTSA	
T13	4	QVQLQSGAELAKPGASVKMSCKASGYTFT	TYWMH	WVKQPPGQGLEWIG	YINP--	STGYTDYNEKFKD	KATLTADKSSSTAYMQLSSLTSEDSAVYVCVR	RGSYDGNPF-----	AY	WGQGTLLVSVSA	
T14	5	EVQLVESGGGLVKPGGSLKLSGCVSGFTFS	DYIMY	WVRQTPKRLWVA	SISS--	GGSYTYSDSVKG	RLTISRDNNTKNLYLQMSLSKSEDTAVYVCVR	GPGGVL-----	DY	WGQGTLLTVSS	
T24	6	QVQLQPGAELVRPGASVKLSCKASGYST	SYWID	WVKQPPGQGLEWIG	NIYP--	SNAYTNYNQKFKD	KATLTVDKSSSTAYMQLSSPTSSEDSAVYVCTS	VLDYFYAM-----	DY	WGQGTSTVTSS	
T25	7	QVTLKESGPGILQPSQTLSTLCTSFSGFSLN	TSGVGVG	WIRQPSGKGLEWLA	HIW---	WDDDERYNPVLKS	RLTISKDTSSNQVFLKIANVDTADSATYVCVR	SMVAMF-----	PY	WGRGTLVTSA	
HeF1-1	8	EVQLVESGGGLVQPGGSLRLSCATSGFTFS	DYYMN	WVRQPPGKALEWIG	FIRNKANGYTT	TEFSASVMG	RFTISRDDSQSILYLQMTLRAEDSATYVCAR	RTETAQASPF-----	DY	WGQGTSTVTSS	
CL2	9	EVQLKQSGTELVRPGASVKLSCKASGYTFT	SYWMH	WVKQPPGQGLEWIG	NINP--	SNGGTNYNEKFKS	KATLTIDKSSSTAYMQLSSLTSEDSAVYVCAR	KTQTITMGF-----	AY	WGQGTLLTVSS	
K1-4	10	QVQLQESGTELAEPGAAYKMSCKASGYTFT	DYWMH	WVKQPPGQGLEWIG	YINP--	NTAYTDYNOQFKD	KATLTADKSSSTAYMQLRSLTSEDSAVYCAK	KTQTITMGF-----	PF	WGQGTLLTVSS	
T420	11	QVQLQSGAELAKPGASVKMSCKASGYTFT	SYWMH	WVKQPPGQGLEWIG	YINP--	STDYTDYNOQFKD	KATLTADKSSSTAYMQLSSLTSEDSAVYCAT	RHYGSSYGF-----	AY	WGQGTLLVTSA	
T427	12	QVQLQPGTELVRLPGASVKLSCKASGSFT	SYWMN	WVKQPPGQGLEWIG	MIHP--	SDSETRLNQKFKD	RATLTVDKSSSTAYMQLSSPTSSEDSAVYVCAS	EMDYFFAM-----	DY	WGQGTSTVTSS	
T405	13	QVQLQIQGAELVRPGASVKLSCKASGYTFN	NYMIN	WVKQPPGQGLEWIG	NIYP--	SDSRSNYNQKFKD	KATLTVDKPSSTAYMQLSSPTSSEDSAVYICTL	GS-----	Y	WGQGTLLVTSA	
T105	14	QVTLKESGPGILQPSQTLSTLCTSFSGFSL	TSGMGVS	WIRQPSGKDLWLA	HIY---	WDDDKRYNPSLKS	RLTISKDTSSNQVELKITSVDTDATATYVCAR	RADGLYFYL-----	DV	WGAGTTVTSS	
T201	38	QVQLKESGPGILVAPSQSLSTICTVSGFSLI	DYGVS	WVRQPPGKGLEWIG	MIW---	GDGNTDYNGLKS	RLSISKDNKSKQVFLKVNLSQTDDTARYVCAR	PSTGTLF-----	AY	WGQGTLLVTSA	
T408	40	QVQLQEPGAELVRPGASVKLSCKASGYTFT	SYWIN	WVKQPPGQGLEWIG	NIYP--	SDSYSNYNQKFKD	KATLTVDKSSSTAYMQLSSPTSSEDSAVYICTL	GS-----	Y	WGQGTLLVTSA	


Fig 2b. Amino acid sequences of the variable regions of anti-CD30 Mabs

SEQ ID NO	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4
VL 123456789012							




Cell Counts

Fig. 3



6/9

FIG. 5



CDC of anti-CD30 antibody in the absence of secondary antibody (15-h postincubation)

Fig. 6A Karpas299 (CD30 positive)





Fig. 6B L540 (CD30 positive)



8/9

Fig. 7B





Fig. 7A



BEST AVAILABLE COPY



Fig. 8A




Fig. 8B




Fig. 8C

